Global Immuno oncology Therapy Market Size By Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors), By Application (Hospitals, Ambulatory Surgical Center), By Region, And Segment Forecasts, 2023...

The Global Immuno-Oncology Therapy Market was valued at USD 24.6 billion in 2023 and is projected to surpass USD 79.4 billion by 2031, growing at a CAGR of 15.7% during the forecast period (2023–2031). The market is driven by the rising incidence of cancer worldwide, increasing adoption of immunotherapy as a frontline treatment, and advancements in immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines. The shift from traditional chemotherapy to targeted, patient-specific therapies has further accelerated investment and innovation in immuno-oncology solutions.

Drivers:

1. Rising Global Cancer Burden:

The growing number of cancer cases globally is prompting healthcare systems to adopt more effective and targeted treatments, making immuno-oncology a critical area of development.

2. Increasing Approvals and R&D Investments:

Continuous FDA approvals and expanding clinical trials across multiple cancer types are supporting market growth. Significant investments by biotech firms and pharmaceutical giants are fostering innovation.

3. Advancements in Personalized Medicine:

Personalized immuno-oncology treatments, including biomarker-driven therapies and genomic profiling, are improving patient outcomes and treatment precision, boosting demand.

Restraints:

1. High Cost of Immunotherapies:

Immuno-oncology treatments are significantly more expensive than conventional therapies, creating accessibility barriers, especially in lower-income economies.

2. Adverse Immune-Related Side Effects:

The possibility of immune system overactivation leading to side effects such as inflammation or autoimmune reactions is a major concern in clinical use.

Opportunity:

1. Expansion into Emerging Markets:

Improving healthcare infrastructure and increasing cancer awareness in regions like Asia-Pacific, Latin America, and the Middle East present substantial growth opportunities.

2. Integration with Artificial Intelligence:

AI integration is accelerating drug discovery, patient selection, and treatment personalization in immuno-oncology, offering new avenues for market players.

Market by System Type Insights:

By system type, Immune Checkpoint Inhibitors held the largest share in 2023 due to their broad efficacy across multiple cancers, including melanoma, lung, and renal cancers. CAR-T Cell Therapy is the fastest-growing segment, propelled by its targeted approach and success in hematological malignancies. Continuous pipeline expansion and new drug launches in this category are expected to sustain its growth trajectory.

Market by End-use Insights:

In terms of end use, Hospitals and Cancer Treatment Centers dominated the market in 2023, accounting for over 55% of total revenue. These institutions are the primary delivery channels for advanced immunotherapies due to their infrastructure, access to specialized personnel, and participation in clinical trials. Academic & Research Institutes are also contributing significantly to innovation and clinical development.

Market by Regional Insights:

North America led the global immuno-oncology therapy market in 2023, owing to its well-established healthcare system, high healthcare expenditure, and presence of leading pharmaceutical companies. Asia-Pacific is anticipated to witness the highest growth rate during the forecast period, driven by increasing cancer prevalence, rapid urbanization, and supportive government healthcare initiatives.

Competitive Scenario:

Key players in the Global Immuno-Oncology Therapy Market include Bristol-Myers Squibb, Merck & Co., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AstraZeneca, Amgen Inc., Gilead Sciences, AbbVie Inc., and Johnson & Johnson. These companies are actively pursuing product innovations, strategic collaborations, and mergers to strengthen their portfolios and global presence.

Key Developments:

In March 2024, Merck announced positive Phase III trial results for its novel PD-L1 inhibitor in triple-negative breast cancer.

In January 2023, Roche introduced a new T-cell engager platform aimed at enhancing tumor-specific immune activation.

In May 2023, Bristol-Myers Squibb expanded its CAR-T manufacturing facilities to meet growing demand globally.

Scope of Work – Global Immuno-Oncology Therapy Market

FAQs

1) What is the current market size of the Global Immuno-Oncology Therapy Market?

The market was valued at USD 24.6 billion in 2023.

2) What is the major growth driver of the Global Immuno-Oncology Therapy Market?

The rising global cancer burden and the growing adoption of personalized immunotherapies are key drivers.

3) Which is the largest region during the forecast period in the Global Immuno-Oncology Therapy Market?

North America is expected to retain the largest market share.

4) Which segment accounted for the largest market share in Global Immuno-Oncology Therapy Market?

Immune Checkpoint Inhibitors held the largest market share in 2023.

5) Who are the key market players in the Global Immuno-Oncology Therapy Market?

Major players include Merck & Co., Bristol-Myers Squibb, Roche, Pfizer, AstraZeneca, and Novartis.